Clinical Summary Authoring Software: Module 2.7 Guide

Assyro publishes this guide; its position is our editorial recommendation, not an independent performance ranking. We reviewed official product descriptions and regulatory sources on September 14, 2026. We did not operate these platforms or benchmark their clinical accuracy. The same must-have gates apply to Assyro and every alternative.

This guide addresses regulatory clinical summaries for pharmaceutical submissions. It does not address encounter notes, hospital discharge summaries, or summaries written for patients. A buyer asking for “clinical summary software” should name the intended CTD section before comparing demonstrations.

A shortlist with the document scope left visible

These are four evaluation candidates with different entry points, not four proven substitutes. AuroraPrime’s page names the required efficacy and safety sections directly. Yseop’s description is narrower. Assyro and Weave require a more explicit document-scope demonstration before they can qualify for a dedicated Module 2.7 authoring purchase.

Define the output before discussing AI

Use ICH M4E(R2) as the content reference for this discussion. The ICH document identifies the current Step 4 version as June 15, 2016; FDA’s corresponding final guidance is dated July 2017. The date of this buyer guide does not imply that a new M4E revision was issued in 2026. ICH M4E(R2), cover and history, FDA final M4E(R2)

The buying boundary is easier to see when the documents are separated:

The overview/summary distinction comes from M4E(R2), sections 2.5 and 2.7. FDA’s integrated-summary guidance explains why an ISS or ISE is not interchangeable with a brief Module 2 summary. Suitable narrative portions can serve both roles with the appropriate cross-references; that does not eliminate the underlying analyses.

Within 2.7, specify biopharmaceutics and associated analytical methods (2.7.1), clinical pharmacology (2.7.2), efficacy (2.7.3), safety (2.7.4), literature references (2.7.5), and individual-study synopses (2.7.6). A product demonstrating only 2.7.4 has not established complete 2.7 coverage. M4E(R2), Clinical Summary contents

For an explanation of the surrounding dossier, use our Module 2 summaries guide. This article focuses on the software purchase: which inputs, controls, and outputs must be demonstrated for the summary work you actually need.

For the source-report drafting purchase, use the CSR writing-software comparison before treating summary generation as equivalent work.

Cross-study reconciliation does not mean making results agree

When studies differ, good authoring preserves the differences needed to interpret them. The software should not quietly relabel populations, normalize unlike endpoints, or rewrite a discordant finding into a single reassuring message.

M4E(R2) addresses study-population differences and cross-study efficacy analyses in 2.7.3.3. Its safety guidance in 2.7.4.2.1 cautions that pooling can obscure differences and calls for an explanation of the pooling rationale. This supports an evaluation that tests whether differences remain visible, rather than rewarding every combined number. M4E(R2), cross-study and safety-analysis sections

Your clinical and statistical reviewers determine which comparisons and analyses are justified. The authoring workflow should carry those decisions into the document, link them to evidence, and expose unresolved questions. If two results disagree, retain both with their study scope and refer the interpretation to the responsible reviewer. An unsupported explanation of the disagreement is another error, even if it sounds scientifically plausible.

How the four candidates differ

Assyro: test the summary-to-submission handoff

Assyro is our first starting point when the team wants to connect document preparation, review, and regulatory operations. Its document management offering is relevant to that broader workflow. The qualification question here is narrower: can the proposed configuration support your specific clinical-summary sections and evidence record?

Assyro’s authority scope distinguishes FDA core functionality, which is generally available, from Health Canada beta and EMA roadmap support. Those platform statuses do not establish that a particular 2.7.3 or 2.7.4 authoring workflow is available. Native Word authoring, automatic cross-study population reconciliation, and exact summary-generation coverage should remain unverified until demonstrated.

For a useful evaluation, bring an approved summary passage, its study source, and a revised table. Ask the team to show how the changed source is associated with the affected document, how a reviewer records a disposition, and how the correct approved output enters the next regulatory step. Record which tasks the platform performs and which remain with the writer or another system.

The potential buying benefit is a clearer handoff between the summary owner and regulatory operations. Measure that handoff directly: can the recipient identify the approved version, source basis, outstanding questions, and output destination without reconstructing the history?

If a proven automated Module 2.7 generator is mandatory immediately, Assyro is not qualified on the evidence in this guide alone. Its first-place position is an invitation to evaluate a conditional fit, not permission to substitute submission functionality for clinical-summary functionality.

AuroraPrime RMA: examine key messages against changing evidence

AlphaLife Sciences’ AuroraPrime RMA has the most explicit section-level description among these candidates: its medical-writing page names 2.7.3 and 2.7.4, CSR-anchored generation, source-linked key messages, and refresh behavior when CSRs change. These are vendor descriptions of the product, not measured results from our testing. AuroraPrime RMA clinical summaries

This makes it a relevant candidate when a team already organizes the summary around reviewed messages and supporting evidence. The important purchase question is whether the message remains subordinate to the evidence. A system that propagates text efficiently can also propagate an outdated assumption if the review boundary is weak.

In a demonstration, approve a narrowly factual statement supported by two study sources. Replace one source with a permitted revision that changes its population definition. Ask which parts of the statement need review and whether the previous wording can remain approved while the evidence has changed. Inspect both the proposed revision and the reviewer’s ability to reject it.

Next, change only a table title. The platform should help distinguish a change that affects interpretation from one that does not. Your team should determine the required response; automatic rewriting of every associated paragraph is not necessarily useful.

Confirm that the proposal is for RMA software with the required clinical-summary workflow. AlphaLife also markets an authoring service; software access, configured templates, and outsourced writing are different commercial deliverables. Ask which configuration work is included and who maintains the message-to-evidence relationships after implementation. AlphaLife regulatory authoring service

Yseop: evaluate the integrated-data boundary for safety summaries

Yseop’s clinical document page names Summary Clinical Safety and describes Module 2 summary automation with integrated databases. It also lists CSRs and clinical trial narratives as distinct document types. This is a concrete reason to investigate a safety-summary workflow, while keeping efficacy-summary support unresolved. Yseop clinical document automation

For a sponsor with prepared integrated outputs, the central question is how their meaning survives the transition into prose. A column labeled “N” is incomplete without its population, treatment group, time period, and counting convention. Ask Yseop to show which metadata are required, which are imported, and what happens when they are absent.

The evaluation should begin with an approved integrated table and its analysis definition, not a request for the writing platform to decide how to pool studies. Follow one count from the source into a generated passage, then supply a second table using a different denominator. The draft should preserve the distinction or stop for clarification.

This approach also exposes implementation work that a polished demonstration may hide. Someone has to establish the input mapping, supply the correct analysis outputs, and maintain them when programming conventions change. Ask who owns each task and whether the same process works with your CRO’s deliverables.

Do not convert a vendor’s accuracy or efficiency claim into an assurance about your safety summary. Agree the exact document, current product configuration, and acceptance sample. A successful safety-summary pilot would establish that bounded workflow; it would not prove automated clinical interpretation or complete Module 2.7 coverage.

Weave Submission Builder: verify source identity across the dossier

Weave describes Submission Builder as a dossier authoring workspace with sentence-level source verification and collaborative document work. Its product page mentions Module 2 summaries and integrated safety and efficacy summaries. That broader scope warrants evaluation when the buyer wants summary work connected to other dossier documents. Weave Submission Builder

However, “Module 2” includes clinical and nonclinical material, and “integrated summary” can mean a different deliverable from 2.7.3 or 2.7.4. Obtain the actual template and output list before treating the product as a dedicated clinical-summary solution.

The distinguishing exercise is source identity. Load two study reports that both contain a table numbered 14.1.1. Have the demonstrator retrieve the source for a sentence using one table. The answer should include the study and document revision, not just the table number or a matching phrase. Then update one report and inspect whether the old draft’s evidence remains reconstructible.

Weave also describes Veeva import/export and source resynchronization. If that connection matters, test the object, version, and direction of transfer you actually use. A resynchronized file is not, by itself, proof that an already approved summary has been reassessed. Weave’s source and integration descriptions

Treat exact document availability, current release scope, and the proposed configuration as contract questions. A broader dossier workflow can be valuable without satisfying every clinical-summary requirement; identify the boundary before deciding which system owns the final review record.

A worked population and source-cutoff exercise

Use the following synthetic procurement exercise to evaluate evidence handling. The counts and study labels are invented solely for document reconciliation. They represent no product, patients, treatment effect, or clinical conclusion. No listed vendor has been tested against this example.

The deliverable is a short population-description passage for a proposed safety summary, accompanied by a source register and unresolved-issue list. Do not ask for an efficacy comparison, a safety conclusion, or a new pooled analysis.

1. Supply deliberately incompatible study extracts

Give the demonstrator these records, preserving their labels exactly:

No approved pooling plan or cross-study participant mapping is supplied at this stage. Do not silently interpret the three counts as the same population. A source register should record the study, table, document revision, population definition, and cutoff separately.

Here is the deliberately defective passage to review:

“

Across the three studies, the safety population comprised 170 unique participants through June 30, 2026.

The arithmetic adds the visible counts, but the sentence fails the evidence contract. It changes Study B’s completer count into a safety-population count, ignores the stated overlap between A and C, and assigns A the later cutoff. The error is not fixed by attaching three citations.

Nor should the tool “repair” the total by subtracting 20 and reporting 150 unique safety participants. That would still merge unlike populations and would assume that all other cross-study overlap is known. The correct response is to retain the study-level records and expose the missing basis for a combined figure.

2. Write the supported description and record the gaps

A defensible response to this limited packet is:

“

The supplied extracts report 80 participants who received at least one dose in Study A at the March 31 cutoff, 60 completers in Study B at the June 30 cutoff, and 30 extension entrants in Study C at the June 30 cutoff. Study C identifies overlap with Study A. These extracts use different population definitions and do not establish a unique combined safety-population count.

This is a reconciliation statement, not a clinical interpretation. Attach A-S v1, B-C v2, and C-E v1 to the corresponding clauses. The issue list should request the intended analysis population, approved source set, participant-overlap handling, and cutoff strategy from the responsible clinical/statistical team.

A missing definition should remain missing. The software should not infer that “completers,” “treated participants,” and “extension entrants” are synonyms because all three tables describe people in the program.

3. Introduce a valid approved output

After completing the first exercise, provide pooled output P-01 v1, explicitly approved for this synthetic scenario. Its accompanying definition states:

• The pool contains Study A and Study B only.
• Both use the specified population of participants who received at least one dose, with the same March 31 cutoff.
• Approved counts are A = 80 and B = 70; there is no participant overlap between these two populations.
• The approved combined count is 150. Study C is outside this particular pool by the supplied analysis specification.

The acceptable passage can now state the 150-participant count for this defined A/B pool at March 31, citing P-01 v1. It must not call that number the entire program population or describe Study C as irrelevant to every safety discussion. B’s 70 in P-01 and its 60 in B-C are not automatically a contradiction: their definitions and cutoffs differ.

The arithmetic check, 80 + 70 = 150, is useful verification of the supplied output. It does not independently validate the pooling method. The approved specification provides the authority for the authoring task.

4. Add a late revision without losing the old basis

Now provide approved P-01 v2. It retains the same pool definition and March 31 cutoff, but a documented source correction changes B from 70 to 72 and the combined count from 150 to 152.

The system should identify the passage and table based on v1 as requiring review, preserve v1’s historical evidence, and propose the corrected count with v2 attached. It should not change the cutoff to the date on which v2 was uploaded. Data cutoff, source publication date, approval date, and upload date are separate fields.

Check the generated file outside the application. The narrative and summary table should agree on 152 after the authorized correction, while the review record identifies what changed. If the text says 152 but the table still says 150, the draft has not passed. If the final file loses the source version, the receiving reviewer cannot reproduce the decision.

Turn the exercise into a purchase decision

Use a simple evidence record for each candidate. Avoid a weighted score that lets attractive drafting features compensate for a failed source or population requirement.

Assign ownership before the demonstration. The writer evaluates the narrative and traceability; clinical/statistical reviewers determine whether definitions and interpretations are appropriate; regulatory operations checks the required output and handoff. Your organization may allocate these roles differently, but none should disappear because a product generates fluent text.

For a buyer needing both 2.7.3 and 2.7.4, Yseop’s cited safety-summary description alone does not establish eligibility for the complete purchase. AuroraPrime has explicit documentation for both sections, making it a focused demo candidate. Assyro and Weave remain conditional until their exact proposed clinical-summary scope is demonstrated.

For a buyer with approved integrated safety outputs, the narrower Yseop workflow may be the relevant evaluation. For a team struggling with source changes across a dossier, test Weave’s source identity and AuroraPrime’s message refresh behavior. For a team prioritizing the handoff into FDA regulatory operations, start with Assyro while keeping clinical-summary automation as a separate acceptance gate.

Ask each vendor to price the same pilot: the agreed sections, study-source count, input formats, reviewer roles, one late revision, and required exports. Separate license costs from source mapping, template configuration, integration, training, validation support, and any authoring service. This guide does not provide comparable verified quotes, so named price estimates would be misleading.

Evaluate the human effort left after generation: how long it takes to inspect the evidence, resolve a mismatch, and prepare the approved output for the next reviewer. Keep those measurements with the exact pilot scope. A faster first paragraph is useful only if the resulting review work is acceptable.

Bring the reconciliation packet to an Assyro workflow demo or the relevant shortlisted vendor. Ask for the supported configuration and preserve the demonstrated source record with the proposal. The purchase should leave your team able to explain what each summary statement describes, which evidence supports it, and who resolved the differences across studies.

Compare the required summary task with Assyro’s regulatory-writing offering, then demonstrate its particular source and review requirements.

Use the AI IND authoring checklist when the summary must join a broader IND preparation workflow.